Discover 62 paid clinical trials in Bowling Green, Kentucky. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 62
Active & Responsive
A Study of Barzolvolimab in Patients With Atopic Dermatitis
for
Atopic Dermatitis
Location: Bowling Green KY, Owensboro KY, Cincinnati OH,
Sponsor: Celldex Therapeutics
Sex: All
Age: 18+
Code: NCT06727552
Phase2, Recruiting
Active & Responsive
A Brief Intervention for Alcohol Users With Interpersonal Trauma
for
Heavy Drinking, Alcohol Drinking, Substance Use,
Location: Bowling Green KY
Sponsor: Western Kentucky University
Sex: All
Age: 18 - 25
Code: NCT05414344
Recruiting
Active & Responsive
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
for
Atoptic Dermatitis
Location: Bowling Green KY, Murfreesboro TN, Wilmington NC,
Sponsor: Evommune, Inc.
Sex: All
Age: 18+
Code: NCT07150845
Phase2, Recruiting
Active & Responsive
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
for
Atopic Dermatitis
Location: Bowling Green KY, Goodlettsville TN, Owensboro KY,
Sponsor: Eli Lilly and Company
Sex: All
Age: 12+
Code: NCT07006792
Recruiting
Active & Responsive
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
for
Plaque Psoriasis
Location: Bowling Green KY, Rolling Meadows IL, Detroit MI,
Sponsor: Oruka Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07090330
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care
for
Arthritis, Rheumatoid
Location: Bowling Green KY, Huntsville AL, Tupelo MS,
Sponsor: Crescendo Bioscience
Sex: All
Age: 18 - 70+
Code: NCT02832297
Recruiting
Active & Responsive
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis